This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Centocor Ortho Biotech Inc., Janssen Biotech, Inc.. Active years: 2011-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2026
Title: Xilin Li: Innovator in Gastrointestinal Disorder Assessment
Introduction
Xilin Li is a notable inventor based in Wallingford, PA (US). He has made significant contributions to the field of gastrointestinal health, particularly in the assessment of disorders such as ulcerative colitis. His innovative approach has the potential to enhance diagnostic and prognostic capabilities in this area.
Latest Patents
Xilin Li holds a patent titled "Methods for assessing response to therapy in subjects having ulcerative colitis." This method provides a prognostic or diagnostic assessment of gastrointestinal-related disorders by correlating the presence, absence, and/or magnitude of a specific gene in a sample with a reference standard. This correlation helps determine the presence and/or severity of the disorder, as well as the response to treatment. The method is designed to identify the effectiveness of candidate therapies, making it a valuable tool in clinical settings.
Career Highlights
Xilin Li is currently associated with Centocor Ortho Biotech Inc., where he applies his expertise in developing innovative solutions for gastrointestinal disorders. His work is instrumental in advancing therapeutic strategies and improving patient outcomes.
Collaborations
Xilin Li collaborates with various professionals in his field, including his coworker, Xiao-yu R Song. Their combined efforts contribute to the ongoing research and development of effective treatments for gastrointestinal disorders.
Conclusion
Xilin Li's contributions to the field of gastrointestinal health through his innovative patent demonstrate his commitment to improving diagnostic and therapeutic methods. His work has the potential to significantly impact patient care and treatment efficacy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
